Abstract
Nitric oxide (NO) is an important gaseous signaling molecule with diverse roles in various physiological processes like maintenance of vascular tone, regulation of metabolism, cell apoptosis etc. NO synthesis in the body is regulated by nitric oxide synthase (NOS); primarily by Ca2+ dependent endothelial and neuronal (eNOS and nNOS), and Ca2+ independent inducible (iNOS) isoforms. Insulin resistance (IR), a critical component in the pathophysiology of lifestyle diseases such as obesity and Type 2 diabetes is characterized by hyperglycemia, dyslipidemia and is also linked to altered gut microbiome. Endothelial dysfunction in obesity and diabetes enhance the risk of cardiovascular complications such as hypertension, atherosclerosis, myocardial infarction, and cerebral stroke. iNOS, which produces high and sustained levels of NO under pathophysiological stimuli is implicated to have deleterious effects on cardiovascular system. During insulin resistant states and its associated complications, iNOS participates in deregulating tissue metabolic processes via imbalance in homeostasis of glucose and lipids as well as endothelial dysfunction through local and systemic inflammatory milieu. This is majorly a resultant of increased nitrosative stress (due to ONOO− release formed by combination of NO and O2 −) which impacts the functions of various proteins involved in maintaining the metabolism and vascular homeostasis by S-glutathionylation of cysteine and/or nitration of tyrosine residues of crucial proteins. Decreased availability of tissue NO in these diseased conditions has opened a new arena of therapeutics focusing on increasing the NO bioavailability via administration of NO precursors such as arginine, nitrite and cell permeable tetrahydrobiopterin analogs on one hand or through a search for selective iNOS inhibitors on the other. This chapter focuses on the role of iNOS in insulin resistance and endothelial functionality through its modulatory effects on tissue metabolism and inflammatory cytokines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:473–481
Ginsberg HN (2000) Insulin resistance and cardiovascular disease. J Clin Invest 106:453–458
Bloomgarden ZT (2007) Insulin resistance, dyslipidemia, and cardiovascular disease. Diabetes Care 30:2164–2170
Bhupathiraju SN, Hu FB (2016) Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res 118:1723–1735
International Diabetes Federation (2017) IDF DIABETES ATLAS Eighth edition. At <file:///C:/Users/HOBBY/Downloads/IDF_DA_8e-EN-final.pdf>
Fang FC (2004) Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2:820–832
Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A (2009) Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 89:27–71
Kanuri BN et al (2018) Glucose and lipid metabolism alterations in liver and adipose tissue pre-dispose p47 phox knockout mice to systemic insulin resistance. Free Radic Res 52:568–582
Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944–948
Berdichevsky A, Guarente L, Bose A (2010) Acute oxidative stress can reverse insulin resistance by inactivation of cytoplasmic JNK. J Biol Chem 285:21581–21589
Kelm M (1999) Nitric oxide metabolism and breakdown. Biochim Biophys Acta Bioenerg 1411:273–289
Levine AB, Punihaole D, Levine TB (2012) Characterization of the role of nitric oxide and its clinical applications. Cardiology 122:55–68
Pautz A et al (2010) Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 23:75–93
Tzeng E, Billiar TR, Robbins PD, Loftus M, Stuehr DJ (1995) Expression of human inducible nitric oxide synthase in a tetrahydrobiopterin (H4B)-deficient cell line: H4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci U S A 92:11771–11775
Mori M, Gotoh T (2000) Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 275:715–719
Saluja R et al (2011) Molecular and biochemical characterization of nitric oxide synthase isoforms and their intracellular distribution in human peripheral blood mononuclear cells. Biochim Biophys Acta, Mol Cell Res 1813:1700–1707
Villanueva C, Giulivi C (2007) Subcellular and cellular locations of nitric-oxide synthase isoforms as determinants of health and disease. Free Radic Biol Med. https://doi.org/10.1016/j.freeradbiomed.2010.04.004
Rana M et al (2015) Turmerone enriched standardized Curcuma longa extract alleviates LPS induced inflammation and cytokine production by regulating TLR4–IRAK1–ROS–MAPK–NFκB axis. J Funct Foods 16:152–163
Charbonneau A, Marette A (2010) Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice potential role of tyrosine nitration of insulin signaling proteins. Diabetes 59:861–871
Nathan C, Xie QW (1994) Nitric oxide synthases: roles, tolls, and controls. Cell 78:915–918
Michel T, Feron O (1997) Nitric oxide synthases: which, where, how, and why? J Clin Invest 100:2146–2152
Kim Y-M, Bergonia H, Lancaster JR (1995) Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. FEBS Lett 374:228–232
Kim F et al (2008) Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 28:1982–1988
Gruber H-J et al (2008) Obesity reduces the bioavailability of nitric oxide in juveniles. Int J Obes 32:826–831
Honing MLH, Morrison PJ, Banga JD, Stroes ESG, Rabelink TJ (1998) Nitric oxide availability in diabetes mellitus. Diabetes/Metab Rev 14:241–249
Perreault M, Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138–1143
Dallaire P et al (2008) Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. Diabetes 57:1999–2011
Sudar E et al (2011) Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. J Physiol Biochem 67:195–204
Duncan ER et al (2008) Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 57:3307–3314
Kanuri BN et al (2017) Altered glucose and lipid homeostasis in liver and adipose tissue pre-dispose inducible NOS knockout mice to insulin resistance. Sci Rep 7:41009
Eriksson JW (2007) Metabolic stress in insulin’s target cells leads to ROS accumulation – a hypothetical common pathway causing insulin resistance. FEBS Lett 581:3734–3742
Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806
Bray GA, Popkin BM (1998) Dietary fat intake does affect obesity! Am J Clin Nutr 68:1157–1173
Liu L et al (2007) Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest 117:1679–1689
Liu Z et al (2015) High-fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. PLoS One 10:e0128274
Xie QW, Kashiwabara Y, Nathan C (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269:4705–4708
Shimabukuro M, Ohneda M, Lee Y, Unger RH (1997) Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest 100:290–295
Noronha BT, Li J-M, Wheatcroft SB, Shah AM, Kearney MT (2005) Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 54:1082–1089
Fujimoto M et al (2005) A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 54:1340–1348
Lumeng CN, DeYoung SM, Bodzin JL, Saltiel AR (2006) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56:16–23
Tannous M et al (1999) Evidence for iNOS-dependent peroxynitrite production in diabetic platelets. Diabetologia 42:539–544
Engeli S et al (2004) Regulation of the nitric oxide system in human adipose tissue. J Lipid Res 45:1640–1648
Meininger CJ et al (2004) GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. FASEB J 18:1900–1902
Choi JW et al (2001) Increases in nitric oxide concentrations correlate strongly with body fat in obese humans. Clin Chem 47:1106–1109
Mercuri F et al (2001) Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44:834–838
Torres SH, De Sanctis JB, de L Briceño M, Hernández N, Finol HJ (2004) Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol 181:419–427
Frisbee JC, Maier KG, Stepp DW (2002) Oxidant stress-induced increase in myogenic activation of skeletal muscle resistance arteries in obese Zucker rats. Am J Physiol Circ Physiol 283:H2160–H2168
House LM et al (2015) Tissue inflammation and nitric oxide-mediated alterations in cardiovascular function are major determinants of endotoxin-induced insulin resistance. Cardiovasc Diabetol 14:56
Sugita H et al (2005) Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 280:14203–14211
Uehara T et al (2006) S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441:513–517
Jeon MJ et al (2012) Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes. Exp Mol Med 44:562
Zanotto TM et al (2017) Blocking iNOS and endoplasmic reticulum stress synergistically improves insulin resistance in mice. Mol Metab 6:206–218
Pilon G et al (2010) Endotoxin mediated-iNOS induction causes insulin resistance via ONOO− induced tyrosine nitration of IRS-1 in skeletal muscle. PLoS One 5:e15912
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 87:91. At <https://www.scopus.com/record/display.uri?eid=2-s2.0-0027459878&origin=inward&txGid=85277588BE5D03F4BA6E74E1DC1E1918.wsnAw8kcdt7IPYLO0V48gA%253a2>
Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM (1994) Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 91:4854–4858
Shinozaki S et al (2011) Liver-specific inducible nitric-oxide synthase expression is sufficient to cause hepatic insulin resistance and mild hyperglycemia in mice. J Biol Chem 286:34959–34975
Spruss A, Kanuri G, Uebel K, Bischoff SC, Bergheim I (2011) Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal 14:2121–2135
Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55:S9–S15
Turinsky J, O’Sullivan DM, Bayly BP (1990) 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 265:16880–16885
Armoni M, Harel C, Bar-Yoseph F, Milo S, Karnieli E (2005) Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements. J Biol Chem 280:34786–34795
Khedara A, Goto T, Morishima M, Kayashita J, Kato N (1999) Elevated body fat in rats by the dietary nitric oxide synthase inhibitor, L -N ω nitroarginine. Biosci Biotechnol Biochem 63:698–702
Cha H-N et al (2010) Lack of inducible nitric oxide synthase does not prevent aging-associated insulin resistance. Exp Gerontol 45:711–718
Cani PD, Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15:1546–1558
Singh A et al (2016) The IRAK-ERK-p67phox-Nox-2 axis mediates TLR4, 2-induced ROS production for IL-1β transcription and processing in monocytes. Cell Mol Immunol 13:745–763
Sugita H et al (2002) Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Metab 282:E386–E394
Ropelle ER et al (2013) Targeted disruption of inducible nitric oxide synthase protects against aging, S-nitrosation, and insulin resistance in muscle of male mice. Diabetes 62:466–470
Ko S-H et al (2008) Inducible nitric oxide synthase-nitric oxide plays an important role in acute and severe hypoxic injury to pancreatic beta cells. Transplantation 85:323–330
Tanioka T et al (2011) Inducible nitric-oxide synthase and nitric oxide donor decrease insulin receptor substrate-2 protein expression by promoting proteasome-dependent degradation in pancreatic β-cells. J Biol Chem 286:29388–29396
Jang JE et al (2016) Nitric oxide produced by macrophages inhibits adipocyte differentiation and promotes profibrogenic responses in preadipocytes to induce adipose tissue fibrosis. Diabetes 65:2516–2528
Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175–184
Lu M et al (2010) Inducible nitric oxide synthase deficiency in myeloid cells does not prevent diet-induced insulin resistance. Mol Endocrinol 24:1413–1422
Epstein FH, Vane JR, Änggård EE, Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27–36
Furchgott RF (1999) Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 19:235–251
Miao C-Y, Li Z-Y (2012) The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol 165:643–658
Muniyappa R, Montagnani M, Koh KK, Quon MJ (2007) Cardiovascular actions of insulin. Endocr Rev 28:463–491
Raghavan SA, Dikshit M (2004) Vascular regulation by the l-arginine metabolites, nitric oxide and agmatine. Pharmacol Res 49:397–414
Kearney MT, Duncan ER, Kahn M, Wheatcroft SB (2008) Insulin resistance and endothelial cell dysfunction: studies in mammalian models. Exp Physiol 93:158–163
Soskić SS et al (2011) Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovasc Med J 5:153–163
Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ (2005) Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group… – PubMed – NCBI. J Hypertens 23:7–17
Cai H, Harrison DG (2011) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. At <http://circres.ahajournals.org/content/87/10/. http://www.lww.com/reprints. http://circres.ahajournals.org/Downloadedfrom>
Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis. JAMA 287:2570
Priya P, Jitendra K, Sanjay R, Kanuri BN, Sachin K, Kumaravelu J, Dikshit (2017) Inducible nitric oxide synthase deficiency preserves vascular function despite systemic insulin resistance in diet-induced mouse model of obesity. In Molecular medicines for lifestyle diseases: emerging targets and approaches, vol 82
Cersosimo E, DeFronzo RA (2006) Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 22:423–436
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625
Yogo K et al (2000) Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arterioscler Thromb Vasc Biol 20:E96–E100
Koglin J, Glysing-Jensen T, Mudgett JS, Russell ME (1998) Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation 97:2059–2065
Hansson GK et al (1994) Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 180:733–738
Kibbe M, Billiar T, Tzeng E (1999) Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 43:650–657
Miyoshi T et al (2006) Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice. Life Sci 79:525–531
Chyu KY et al (1999) Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ Res 85:1192–1198
Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL (2001) Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103:3099–3104
Tsuchiya K et al (2012) FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab 15:372–381
Dimmeler S et al (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601–605
Hsueh WA, Law RE (1999) Insulin signaling in the arterial wall. Am J Cardiol 84:21–24
Marasciulo FL, Montagnani M, Potenza MA (2006) Endothelin-1: the yin and yang on vascular function. Curr Med Chem 13:1655–1665
Montagnani M et al (2002) Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 277:1794–1799
Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605
Paneni F, Beckman JA, Creager MA, Cosentino F (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34:2436–2443
Janus A, Szahidewicz-Krupska E, Mazur G, Doroszko A (2016) Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders. Mediat Inflamm 2016:3634948
Kaiser N et al (1993) Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42:80–89
Pieper GM, Riaz-ul-Haq (1997) Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol 30:528–532
Williams B, Gallacher B, Patel H, Orme C (1997) Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 46:1497–1503
Li H, Li H, Bao Y, Zhang X, Yu Y (2011) Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-κB pathway in rat aorta. Int J Cardiol 152:218–224
Inoguchi T et al (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939–1945
Mathew M, Tay E, Cusi K (2010) Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 9:9
Baker RG, Hayden MS, Ghosh S (2011) NF-κB, inflammation, and metabolic disease. Cell Metab 13:11–22
Paulus WJ, Frantz S, Kelly RA (2001) Nitric oxide and cardiac contractility in human heart failure: time for reappraisal. Circulation 104:2260–2262
Haywood GA et al (1996) Expression of inducible nitric oxide synthase in human heart failure. Circulation 93:1087–1094
Heusch P et al (2010) Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S -nitrosylation. Am J Physiol Circ Physiol 299:H446–H453
Vejlstrup NG et al (1998) Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol 30:1215–1223
Zhang C et al (2005) TNF- contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 26:475–480
Drexler H, Hornig B (1999) Endothelial dysfunction in human disease. J Mol Cell Cardiol 31:51–60
Liu Y-H et al (2005) Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 289:H2616–H2623
Xi L, Jarrett NC, Hess ML, Kukreja RC (1999) Myocardial ischemia/reperfusion injury in the inducible nitric oxide synthase knockout mice. Life Sci 65:935–945
Sam F et al (2001) Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res 89:351–356
Rösen P, Ballhausen T, Stockklauser K (1996) Impairment of endothelium dependent relaxation in the diabetic rat heart: mechanisms and implications. Diabetes Res Clin Pract 31:S143–S155
Nitenberg A et al (1993) Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42:1017–1025
Mungrue IN et al (2002) Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 109:735–743
Guo Y et al (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 96:11507–11512
Prakash P et al (2011) Atorvastatin protects against ischemia-reperfusion injury in fructose-induced insulin resistant rats. Cardiovasc Drugs Ther 25:285–297
Lee JK, Borhani M, Ennis TL, Upchurch GR, Thompson RW (2001) Experimental abdominal aortic aneurysms in mice lacking expression of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 21:1393–1401
Prakash R et al (2012) Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes 61:1533–1542
Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC (2012) Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets 12:148–158
Last D et al (2007) Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care 30:1193–1199
Moskowitz MA, Lo EH, Iadecola C (2010) The science of stroke: mechanisms in search of treatments. Neuron 67:181–198
Calvert JW, Lefer DJ (2010) Clinical translation of nitrite therapy for cardiovascular diseases. Nitric Oxide 22:91–97
Shukla A, Dikshit M, Srimal RC (1995) Nitric oxide modulates blood-brain barrier permeability during infections with an inactivated bacterium. Neuroreport 6:1629–1632
Faraci FM, Brian JE (1994) Nitric oxide and the cerebral circulation. Stroke 25:692–703
Zheng Z, Yenari MA (2004) Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res 26:884–892
Danton GH, Dietrich WD (2003) Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62:127–136
Rosenberg GA (1999) Ischemic brain edema. Prog Cardiovasc Dis 42:209–216
Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391–397
Endoh M, Maiese K, Wagner J (1994) Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 651:92–100
Iadecola C, Zhang F, Xu S, Casey R, Ross ME (1995) Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 15:378–384
Chan PH (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21:2–14
Iadecola C, Zhang F, Xu X (1995) Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol Integr Comp Physiol 268:R286–R292
Zhao X, Haensel C, Araki E, Ross ME, Iadecola C (2000) Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res 872:215–218
Członkowska A, Cyrta B, Korlak J (1979) Immunological observations on patients with acute cerebral vascular disease. J Neurol Sci 43:455–464
Prass K et al (2003) Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1–like immunostimulation. J Exp Med 198:725–736
Korhonen P et al (2015) Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain Behav Immun 49:322–336
Benakis C et al (2016) Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med 22:516–523
Hum PD et al (2007) T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab 27:1798–1805
Gan Y et al (2014) Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci 111:2704–2709
Liesz A et al (2009) Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 15:192–199
Kim J, Montagnani M, Koh KK, Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113:1888–1904
Jain M, Barthwal MK, Haq W, Katti SB, Dikshit M (2012) Synthesis and pharmacological evaluation of novel arginine analogs as potential inhibitors of acetylcholine-induced relaxation in rat thoracic aortic rings. Chem Biol Drug Des 79:459–469
Jun T, Wennmalm A (1994) NO-dependent and -independent elevation of plasma levels of insulin and glucose in rats by L-arginine. Br J Pharmacol 113:345–348
Piatti PM et al (2001) Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 24:875–880
Bogdanski P et al (2012) Effect of 3-month L-arginine supplementation on insulin resistance and tumor necrosis factor activity in patients with visceral obesity. At <https://www.europeanreview.org/wp/wp-content/uploads/1081.pdf>
Lucotti P et al (2006) Beneficial effects of a long-term oral l -arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Metab 291:E906–E912
La Mura V et al (2014) Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase. J Hepatol 61:1321–1327
Darley-Usmar V, Wiseman H, Halliwell B (1995) Nitric oxide and oxygen radicals: a question of balance. FEBS Lett 369:131–135
Wei C-L, Hon W-M, Lee K-H, Khoo H-E (2005) Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct-ligated rats. Liver Int 25:647–656
King DE, Mainous AG III, Geesey ME (2008) Variation in L-arginine intake according to demographic characteristics and cardiovascular risk. Nutr Res 28:21
Tsutsui M et al (2015) Significance of nitric oxide synthases: lessons from triple nitric oxide synthases null mice. J Pharmacol Sci 127:42–52
Sansbury BE, Hill BG (2014) Regulation of obesity and insulin resistance by nitric oxide. Free Radic Biol Med 73C:383–399
Rafikov R et al (2011) eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 210:271–284
Abudukadier A et al (2013) Tetrahydrobiopterin has a glucose-lowering effect by suppressing hepatic gluconeogenesis in an endothelial nitric oxide synthase–dependent manner in diabetic mice. Diabetes 62:3033–3043
Shimazu T et al (2011) Sepiapterin enhances angiogenesis and functional recovery in mice after myocardial infarction. Am J Physiol Circ Physiol 301:H2061–H2072
Varadharaj S et al (2017) Role of dietary antioxidants in the preservation of vascular function and the modulation of health and disease. Front Cardiovasc Med 4:64
Yang Y, Loscalzo J (2005) S-nitrosoprotein formation and localization in endothelial cells. Proc Natl Acad Sci 102:117–122
Daaka Y (2012) S-nitrosylation-regulated GPCR signaling. Biochim Biophys Acta 1820:743–751
Al-Ani B et al (2006) The release of nitric oxide from S-nitrosothiols promotes angiogenesis. PLoS One 1:e25
Kleinbongard P et al (2003) Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35:790–796
Moncada S, Rees DD, Schulz R, Palmer RM (1991) Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A 88:2166–2170
Park J-H et al (2002) Nitric oxide (NO) pretreatment increases cytokine-induced NO production in cultured rat hepatocytes by suppressing GTP cyclohydrolase I feedback inhibitory protein level and promoting inducible NO synthase dimerization. J Biol Chem 277:47073–47079
Carvalho-Filho MA et al (2005) S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt. Diabetes 54:959–967
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Aggarwal, H., Kanuri, B.N., Dikshit, M. (2019). Role of iNOS in Insulin Resistance and Endothelial Dysfunction. In: Chakraborti, S., Dhalla, N., Ganguly, N., Dikshit, M. (eds) Oxidative Stress in Heart Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-13-8273-4_21
Download citation
DOI: https://doi.org/10.1007/978-981-13-8273-4_21
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-8272-7
Online ISBN: 978-981-13-8273-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)